Activists seek dialogue on controlled Human infection trials policy

Subject :Science and technology

Section: Health

Context:

The group, including an advocate, researcher, journalist and others, have submitted a 15-page document calling for more transparency, clear definitions of ‘deliberate infection’ and ‘deliberate harm’ and specific assurances on compensation for adverse events.

Details:

The group has sought to know how CHIS can take place when laws such as the Madras Public Health (Amendment) Act 1958, state that any act performed with a deliberate intention to cause an infection, is illegal.
A CHIS may be in direct contravention of Acts such as this one.
It calls for information on the capacity, effectiveness and efficiency of current regulatory mechanisms for clinical trials.
It has also called for the publication of all results of CHIS – including of failed CHIS, and negative results.
These publications must include a clear estimation of adverse events and harms.

Adverse events:

The group demands for:
Assurance of compensations in case a person is adversely injured.
All those involved should be accountable for adverse events.
The drug control regulators’ ethical obligations must be specified
Creation of a separate section for complete details of safety requirements.
ICMR statement should describe a “knowledge threshold” so that healthy participants in the drug trial are not exposed to something about which the researchers do not have adequate knowledge.
The terms “Deliberate infection” and “Deliberate harm” must be defined and the conceptual difference between the two explained.